Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Approval for Genentech's vismodegib marked the first approval for a Hedgehog inhibitor, but questions remain for the class's broader role in other cancers.
Trevor Mundel, new President of Global Health at the Bill & Melinda Gates Foundation, discusses his plans for a high-throughput approach to translational research.
Rare diseases affect, by definition, only a small number of people. This article investigates how drug development for rare diseases can provide attractive opportunities for biopharmaceutical industries.
Fusion protein that inhibits vascular endothelial growth factor signalling approved in the United States for the treatment of neovascular age-related macular degeneration.
New insights into the mechanisms underlying atrial fibrillation have identified promising new approaches to prevent the fundamental processes that lead to the generation of arrhythmia. Dobrev and colleagues discuss the rationale for developing new anti-atrial fibrillation drugs, the molecular and structural motifs that they target, and the results obtained in experimental and clinical studies.
Dual enkephalinase inhibitors and fatty acid amide hydrolase inhibitors increase the levels of endogenous opioids and cannabinoids, respectively. Although their antinociceptive effects have been known for over a decade, they have only recently entered early-stage clinical trials. This Review compares the effects of these two potential classes of novel analgesics and discusses opportunities for combination therapies.
Antibody Fc receptors (FcRs) connect innate and adaptive immune responses, and present attractive targets for the treatment of inflammatory diseases, cancer and infection. In this Review, Hogarth and Pietersz review the unique opportunities and challenges presented by this receptor class, and discuss the various strategies to manipulate FcR function.
